ClinicalTrials.gg
RecruitingNCT05283226Updated Jan 23, 2026

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

A Phase 2 interventional study of NRC-2694-A and Paclitaxel in Carcinoma and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by NATCO Pharma Ltd.. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by NATCO Pharma Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 403 studies in Carcinoma with a site in United States — 71 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.

Planned enrollment
275th of 359
21 · median 48
Started
2022
with 25 others
Phase 2
117 of 403
25 open now
Primary completion
2026-12
later than 25 of 109 live
Registered
329th of 403
by date

Among the 403 studies in Carcinoma with a site in United States, this one is the 275th largest by planned enrollment of the 359 interventional ones that give a count, is one of 26 that started in 2022, is one of 117 in phase 2, reaches primary completion later than 25 of the 109 other live ones, and was the 329th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

71 of the 403 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 403 studies in Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy.

A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.

Read the detailed description

Patients with recurrent and/or metastatic unresectable Head and Neck Cancer have a poor prognosis and limited treatment options. Pembrolizumab and Nivolumab, both ICIs (Immune Checkpoint Inhibitors), are approved therapies for this condition. However, no approved treatment options exist for patients who progress on ICI therapies. Hence, there is an unmet medical need post-failure of ICI therapy. NRC-2694-A is an orally administered small-molecule tyrosine kinase inhibitor. It was discovered and developed by NATCO Pharma Ltd. NRC-2694-A demonstrated response in HNSCC patients in a Phase-I study as a monotherapy. This was further substantiated in a Phase-II study in combination with cisplatin/carboplatin and paclitaxel.

03

Conditions studied

  • Carcinoma
  • Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Browse trials for

Keywords

  • Carcinoma
  • Recurrent and/or Metastatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is willing and capable of understanding the written , provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.
  • Is male or female aged 18 years or older at the time of consent.
  • Has confirmed unresectable R/M HNSCC (oral cavity, oropharynx, hypopharynx, and larynx).
  • Has documented progressive disease assessed by the principal investigator according to v1.1.
  • Has a per RECIST v1.1.
  • Has performance status score of ≤2.
  • Must have progressed during or after receiving ICI therapy, such as pembrolizumab or nivolumab. Patients with prior immune-mediated reactions due to ICI therapies (eg, pembrolizumab or nivolumab) and who had recovered prior to study entry will also be eligible.
  • Female patients of should have a negative urine test before enrollment. If the urine pregnancy test is positive or gives equivocal results, a serum pregnancy will be required for confirmation.
  • Patients of reproductive age must use acceptable methods of throughout the study period and for 30 days following the last dose of product (see protocol for further guidance).
  • During screening and at subsequent visits, the investigator should ensure adequate bone marrow reserve ( ≥1500/mm3, count ≥100,000/mm3, and level 8.0 g/dL), renal function ( ≥30 mL/min calculated by Cockcroft-Gault formula), liver function (total level ≤1.5 × [except patients with documented Gilbert's syndrome] and serum transaminase levels ≤2.5 × ULN or ≤5 × ULN for liver and/or obstructive jaundice).
  • Must have completed a duration of at least two weeks after stopping ICI therapy/investigational therapy/salvage therapy and must have recovered to grade ≤1 from all toxicities due to such therapies.

Exclusion criteria

Exclusion Criteria:

  • Has cardiac, hepatic, endocrine, pulmonary, or disease, interstitial lung disease, renal or psychiatric disorders, not controlled with therapy corresponding to the illness or a condition that contraindicates the use of a taxane or an EGFR inhibitor.
  • Has Cirrhosis of liver at a level of B (or worse).
  • Has uncontrolled . Patients are allowed if brain metastasis has been previously treated with surgery, whole brain irradiation, and/or stereotactic radiosurgery and are considered controlled (controlled by the dose ≤10 mg/day of prednisone or equivalent) at the time of the first dose of product. Radiological evaluation of brain metastasis will be performed only if the patient has symptoms. For asymptomatic patients, brain imaging during screening is not required.
  • Has baseline prolongation of /QTc interval (eg, repeated demonstration of a QTc interval >480 milliseconds [ Grade 1] using Fredericia's QT correction formula).
  • Has a history of additional risk factors for Torsade de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
  • Has had prior cetuximab therapy for recurrent or disease. Note that cetuximab used concomitantly with radiotherapy or as an induction therapy is acceptable
  • Has received any other EGFR-targeted therapies for recurrent or metastatic disease.
  • Currently participating in any clinical trial or receiving investigational therapy on expanded access or compassionate basis.
  • Has nasopharyngeal carcinomas or salivary gland cancers.
  • Female patient who tested positive for pregnancy.
  • Female patient who is breastfeeding or planning to become pregnant, or male patient planning to father a child within the duration of the study.
  • Has tested positive for , , antibody, or HCV RNA at screening. However, patients who test positive for HCV antibody, but negative for HCV RNA, will be allowed. In addition, patients with controlled HIV, chronic HBV on suppressive antiviral therapy, or a history of HCV infection status post-curative antiviral treatment with an HCV viral load below limit of quantification are permitted to participate (DHHS 2020).
  • Has active infection requiring intravenous anti-infective therapy within 7 days prior to Day 1 Cycle 1 or is febrile due to infection.
  • Has had major surgery within 4 weeks prior to screening.
  • Administered a within 4 weeks prior to Day 1 Cycle 1 or anticipation that such a live attenuated vaccine will be required during the study.
  • Has known or suspected to any components of the formulation used for this investigational product.
  • Has concurrent disease or any abnormality following the investigator's review of the screening physical examination findings, 12-lead results, and clinical laboratory tests, which in the judgment of the investigator would interfere with the patient's participation in this study or evaluation of study results.
  • Unable to come for study visits per schedule.
  • Has current drug or alcohol abuse.
  • Has received prior treatment with paclitaxel or docetaxel or any other drugs with taxane like mode of action for recurrent or metastatic or recurrent HNSCC. However, prior paclitaxel or docetaxel or any other drugs with taxane like mode of action as a component of a curatively-intended multimodality treatment for locally advanced HNSCC is permitted.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    NRC-2694-A In Combination with paclitaxel

    Patients will receive NRC-2694-A 300 mg orally once daily and paclitaxel 175 mg/m² IV infusion over approximately 3 hours once in 21 days for 6 cycles or more.

    Drug: NRC-2694-A · Drug: Paclitaxel

Interventions

  • DrugNRC-2694-A

    300 mg orally once daily

  • 175 mg/m² IV infusion over approximately 3 hours

06

What researchers measure

Primary outcomes

  1. To determine if NRC-2694-A administered orally in combination with paclitaxel demonstrates objective response in patients with R/M HNSCC, who have had radiological progression on or after treatment with ICI therapies like pembrolizumab or nivolumab

    Objective response in terms of CR/PR per RECIST v1.1

    Time frame: Baseline through approximately up to 24 weeks

Secondary outcomes

  1. Progression-free survival

    defined as the interval of time between the date of enrollment to the earliest date of disease progression, as determined by local radiologic assessment per RECIST v1.1, or death due to any cause, whichever occurs first

    Time frame: Baseline through approximately up to 24 weeks

  2. Overall survival

    defined as the time from the date of enrollment to the date of death due to any cause

    Time frame: Baseline through approximately up to 24 weeks

  3. Duration of response

    defined as the time from first confirmed objective response to disease progression

    Time frame: Baseline through approximately up to 24 weeks

  4. Clinical benefit response

    defined as CR + PR + SD for ≥ 6 months

    Time frame: Baseline through approximately up to 26 weeks

  5. Number of adverse events

    Time frame: Baseline through approximately up to 24 weeks

  6. Number of participants with abnormal physical examination findings

    Symptom-directed physical examination will be conducted to evaluate skin rash, diarrhea, paresthesia, and dyspnea graded according to NCI CTCAE version 5.0.

    Time frame: Baseline through approximately up to 24 weeks

  7. Number of participants with abnormal vital signs

    Clinically significant abnormal blood pressure, heart rate, respiratory rate, and oral body temperature graded according to NCI CTCAE version 5.0.

    Time frame: Baseline through approximately up to 24 weeks

  8. Assessing safety through ECOG (Eastern Cooperative Oncology Group)

    The severity of the AE will be graded according to the NCI CTCAE version 5.0 (NCI Common Terminology Criteria for Adverse Events. The CTCAE displays Grades 1 through Grade 5 with the higher score as worse outcome)

    Time frame: Baseline through approximately up to 24 weeks

  9. Number of participants with abnormal clinical laboratory tests results

    Clinically significant abnormal hematology, biochemistry, coagulation and urinalysis test results graded according to NCI CTCAE version 5.0.

    Time frame: Baseline through approximately up to 24 weeks

  10. Number of participants with abnormal ECGs (Electrocardiograms)

    Clinically significant abnormal ECG findings will be graded per NCI CTCAE version 5.0.

    Time frame: Baseline through approximately up to 24 weeks

  11. Plasma PK parameters of NRC-2694-A measured via Cmax (Maximum plasma concentration)

    Time frame: Baseline through approximately up to 24 weeks

  12. Plasma PK parameters of NRC-2694-A measured via Tmax (time to reach the maximum plasma concentration)

    Time frame: Baseline through approximately up to 24 weeks

  13. Plasma PK parameters of NRC-2694-A measured via Ctrough (observed trough plasma concentration at the dosing interval tau)

    Time frame: Baseline through approximately up to 24 weeks

  14. Plasma PK parameters of NRC-2694-A measured via AUC0-t (area under the concentration-time curve from time zero to the time of last measurable concentration)

    Time frame: Baseline through approximately up to 24 weeks

  15. Plasma PK parameters of NRC-2694-A measured via AUC0-τ (area under the concentration-time curve from time zero to the dosing interval tau)

    Time frame: Baseline through approximately up to 24 weeks

  16. Plasma PK parameters of NRC-2694-A measured via CL/F (apparent clearance)

    Time frame: Baseline through approximately up to 24 weeks

  17. Plasma PK parameters of NRC-2694-A measured via Vz/F (apparent volume of distribution)

    Time frame: Baseline through approximately up to 24 weeks

  18. Plasma PK parameters of NRC-2694-A measured via Rac Cmax (accumulation ratio based on maximum plasma concentration)

    Time frame: Baseline through approximately up to 24 weeks

  19. Plasma PK parameters of NRC-2694-A measured via Rac AUC (accumulation ratio based on area under the concentration-time curve)

    Time frame: Baseline through approximately up to 24 weeks

Other outcomes

  1. To determine the association between NRC-2694-A activity and biomarkers in blood samples using Epidermal growth factor receptor status in EGFR (epidermal growth factor receptor) gene

    as determined by NeoLAB® NGS platform biomarker assessment

    Time frame: Baseline through approximately up to 24 weeks

  2. To determine the association between NRC-2694-A activity and biomarkers in blood samples using downstream signaling in EGFR gene

    as determined by NeoLAB® NGS platform biomarker assessment

    Time frame: Baseline through approximately up to 24 weeks

  3. To determine the association between NRC-2694-A activity and biomarkers in blood samples using mutations in EGFR gene

    as determined by NeoLAB® NGS platform biomarker assessment

    Time frame: Baseline through approximately up to 24 weeks

07

Study locations

1 of 13 sites recruiting
  • Providence Medical Foundation -Fullerton
    Fullerton, California 92835, United States
    Completed

    Not enrolling at this site.

  • Los Angeles Hematology Oncology Medical Group
    Los Angeles, California 90017, United States
    Completed

    Not enrolling at this site.

  • Lynn Cancer Center
    Boca Raton, Florida 33486, United States
    Completed

    Not enrolling at this site.

  • Miami Cancer Center
    Miami, Florida 33176, United States
    Completed

    Not enrolling at this site.

  • Norton Cancer Institute - Downtown
    Louisville, Kentucky 40202, United States
    Completed

    Not enrolling at this site.

  • University of Maryland Greenebaum Cancer Center
    Baltimore, Maryland 21201-1544, United States
    Completed

    Not enrolling at this site.

  • Washington University - Siteman Cancer Center
    St Louis, Missouri 63110, United States
    Completed

    Not enrolling at this site.

  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756-1000, United States
    Completed

    Not enrolling at this site.

  • Salib Oncology
    Easton, Pennsylvania 18045, United States
    Completed

    Not enrolling at this site.

  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
    Completed

    Not enrolling at this site.

  • Daycare Angels under AOH
    Mumbai, Maharashtra 40001, India
    Recruiting
  • Grant Medical Foundation Ruby Hall Clinic
    Pune, Maharashtra 411001, India
    Completed

    Not enrolling at this site.

  • Basavatarakam Indo American Cancer Hospital & Research Institute
    Hyderabad, Telangana 500034, India
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 82 phase 2 interventional studies under Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 88. This study's planned 51 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Mar 16, 2022
StartActual
Sep 30, 2022
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05283226
Lead sponsor
NATCO Pharma Ltd.
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
Sep 30, 2022
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Praveen Myneni, MBBS
Contact
drpraveen@natcopharma.co.in
+91 40 23547532

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion